Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Stroke
ThromboGenics initiates trial evaluating microplasmin for intra-arterial treatment of stroke
October 25th, 2006
ThromboGenics NV, a biotechnology company focused on vascular disease, announced initiation of a phase 2a clinical trial to evaluate microplasmin for the intra-arterial treatment of stroke. The study, which is called the Microplasmin MITI-IA trial (Microplasmin In Treatment of Ischemic Stroke - Intra-Arterial), is the second study that ThromboGenics has initiated to assess the benefits of microplasmin for the treatment of acute ischemic stroke. The first study, called MITI-IV, is evaluating the intravenous administration of microplasmin for the treatment of acute stroke. Preliminary results from the MITI-IV trial, which is ongoing, are expected to be available in the...
Source: Biotech Week (2006-10-25)
|
